Results 191 to 200 of about 255,745 (263)

Global burden of peripheral arterial disease and its risk factors, 1990-2021. [PDF]

BMC Cardiovasc Disord
Fu M, Zhang H.
europepmc   +1 more source

Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In patients with myocardial infarction (MI), quantifying expression of platelet FcɣRIIa (pFCG) stratifies risk of subsequent MI, stroke, and death. Aims Assess the prognostic implications of clinical risk alone and in combination with the pFCG test.
David J. Schneider, Sean R. McMahon, Dominick J. Angiolillo, Alexander C. Fanaroff, Homam Ibrahim, Patrick K. Hohl, Brett L. Wanamaker, Mark B. Effron, Peter M. DiBattiste, behalf of the investigators   +9 more
wiley   +1 more source

PM_2.5 and its chemical components interact with hypoxia to increase the risk of hospitalization for peripheral arterial disease. [PDF]

Eco Environ Health
He L, Liu C, Zhou B, Zhao H, Yang Z, Zhou E, Chen H, Wei H, Guoji Q, He Y, Luo B.   +10 more
europepmc   +1 more source

Protective Effect of Phytic Acid in Cardiovascular Diseases: A Systematic Review

ChemFoodChem, EarlyView.
ABSTRACT Cardiovascular diseases (CVDs) are a cluster of ailments that impact the heart and blood vessels and are a primary public health problem of mortality on a global scale. Phytic acid, a dietary constituent frequently present in foods like seeds, has been linked to many pharmacological attributes, including anti‐cancer, antioxidant, anti ...
Marta M. S. de Freitas Almeida, Éverton A. Pereira, Patricia Severino, Cristina Blanco‐Llamero, Sandra L. Santos, Luciana N. Andrade, Ricardo G. Amaral, Eliana B. Souto   +7 more
wiley   +1 more source

The metabolic score for visceral fat and risk of peripheral arterial disease in hypertension patients: a prospective cohort study. [PDF]

Front Endocrinol (Lausanne)
Li S, Yan C, Wu M, Wang T, Zhu L, Yu C, Zhang W, Zhou W, Bao H, Cheng X.   +9 more
europepmc   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis. [PDF]

Diabetes Ther
Elliott B, Tomlinson E, Desai N, Heald A, Field BC, Heiss C, Whyte MB.   +6 more
europepmc   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source